Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024.The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of option and evaluation deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities.Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.Chapter 3 provides an overview of the structure of option and evaluation deals.Chapter 4 provides a review of the leading option and evaluation deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.Chapter 6 provides a comprehensive and detailed review of option and evaluation deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.The deal directory includes a comprehensive listing of all option and evaluation deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.The report also includes numerous table and figures that illustrate the trends and activities in option and evaluation dealmaking since 2016.In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:Understand deal trends since 2016Browse option and evaluation dealsBenchmark analysis - identify market value of transactionsFinancials termsDirectory of deals by company A-Z, therapy focus and technology typeLeading deals by valueMost active dealmakersIdentify assets and deal terms for each transactionAccess contract documents - insights into deal structuresDue diligence - assess suitability of your proposed deal terms for partner companiesSave hundreds of hours of research timeReport ScopeOption and Evaluation Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.Option and Evaluation Deals in Pharmaceuticals and Biotechnology includes:Trends in option and evaluation dealmaking in the biopharma industryOverview of option and evaluation deal structureDirectory of option and evaluation deal records covering pharmaceutical and biotechnologyThe leading option and evaluation deals by valueMost active option and evaluation dealmakersThe leading option and evaluation partnering resourcesIn Option and Evaluation Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:Company A-ZHeadline valueTherapeutic areaTechnology typeEach deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for option and evaluation deals, including contract documents where available.Analyzing contract agreements allows due diligence of:What are the rights granted or optioned?What rights are granted by the agreement?What exclusivity is granted?What is the payment structure for the deal?How are sales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are intellectual property rights handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?

Collaboration Deals in Pharmaceuticals 2019-2024

Collaboration Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter collaboration deals.Fully revised and updated, the report provides details of collaboration deals from 2019 to 2024.The report provides access to collaboration deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of collaboration deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaboration contract documents as submitted to the Securities Exchange Commission by companies and their partners.The initial chapters of this report provide an orientation of collaboration dealmaking and business activities.Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in collaboration as well as a discussion on the merits of the type of deal.Chapter 3 provides an overview of the structure of collaboration deals.Chapter 4 provides a review of the leading collaboration deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.Chapter 5 provides a comprehensive listing of the top 25 most active collaboration dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.Chapter 6 provides a comprehensive and detailed review of collaboration deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the collaboration deal.The deal directory includes a comprehensive listing of all collaboration deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.The report also includes numerous table and figures that illustrate the trends and activities in collaboration dealmaking since 2019.In conclusion, this report provides everything a prospective dealmaker needs to know about collaboration alliances.Collaboration Deals in Pharmaceuticals provides the reader with the following key benefits:Understand deal trends since 2019Browse collaboration dealsBenchmark analysis - identify market value of transactionsFinancials terms - upfront, milestone, royaltiesDirectory of deals by company A-Z, therapy focus and technology typeLeading deals by valueMost active dealmakersIdentify assets and deal terms for each transactionAccess contract documents - insights into deal structuresDue diligence - assess suitability of your proposed deal terms for partner companiesSave hundreds of hours of research timeReport ScopeCollaboration Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the collaboration trends and structure of deals entered into by leading biopharma companies worldwide.Collaboration Deals in Pharmaceuticals includes:Trends in collaboration dealmaking in the biopharma industryOverview of collaboration deal structureDirectory of collaboration deal records covering pharmaceutical and biotechnologyThe leading collaboration deals by valueMost active collaboration dealmakersThe leading collaboration partnering resourcesIn Collaboration Deals in Pharmaceuticals, the available deals are listed by:Company A-ZHeadline valueTherapeutic areaTechnology typeEach deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.Collaboration Deals in Pharmaceuticals provides comprehensive access to available records for collaboration deals, including contract documents where available.Analyzing contract agreements allows due diligence of:What are the rights granted or optioned?What rights are granted by the agreement?What exclusivity is granted?What is the payment structure for the deal?How are sales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are intellectual property rights handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What subcollaboration and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?

The Global Market for Metal-organic Frameworks (MOFs) 2024-2035

Metal-organic frameworks, or MOFs, are highly crystalline, porous materials with nanometre-sized pores and large internal surface areas. Their structures make them useful for applications such as carbon capture, adsorption of greenhouse gas methane, and dehumidification of air for room climate control.  MOFs exhibit unique physicochemical properties, including high surface area, ultra-high porosity, low crystal density as well as remarkable thermal and chemical stabilities. 

Industrial Automation and Wireless IoT - 5th Edition

The Installed Base of Wireless Devices in Industrial Automation Reached 56.5 Million in 2023 This study investigates the worldwide market for wireless IoT applications in industrial automation. The installed base of active wireless IoT devices in the industrial automation industry is forecasted to grow at a compound annual growth rate of 14.3% from 56.5 million units at the end of 2023 to 110.3 million units by 2028. Get up to date with the latest information about vendors, products and markets. Highlights from the report:

Global LPG Market Analysis Plant Capacity, Location, Production, Operating Efficiency, Demand & Supply, End Use, Regional Demand, Sales Channel, Foreign Trade, Manufacturing Process, Industry Market Size, 2015-2035

Quick Summary:In the rapidly modernizing world of technology, staying updated with key market trends is crucial to maintaining a competitive edge. With this in mind, we are excited to present a detailed market report on the global Liquefied Petroleum Gas (LPG) market. The report encapsulates the global market's dynamics, providing a comprehensive overview of demand and supply, production capacity, and consumption trends by region and application.Understanding the LPG market's expansion is critical, given its pivotal role as a clean, efficient energy source. Increased urban population growth, improved R&D activities, and growing environmental awareness place LPG as a promising alternative to traditional energy sources. Consequently, this report offers invaluable insights into the various end-use sectors, including the residential sector, where LPG has gained significant traction for household activities.Furthermore, the report portrays a detailed picture of the global LPG production landscape, divulging the key market players' activities. Understanding the production capacity, export/import trends, and market share in different regions can significantly benefit prospective investors and stakeholders alike, assisting making informed commercial decisions.Through use of this meticulous research report, industry stakeholders can tap the emerging opportunities in the global LPG market, devise strategic plans, and ultimately accelerate their growth trajectory. Global LPG demand stood at 280 million tonnes in 2019 and is anticipated to grow at around CAGR 7.15% during the forecast period.

Nannochloropsis Market Size, Share, Forecast, & Trends Analysis by Form, Application - Global Forecast to 2031

Nannochloropsis Market Size, Share, Forecast, & Trends Analysis by Form (Frozen, Liquid, Powder, Fresh Pastes), Application (Aquafeed, Extraction Companies)-Global Forecast to 2031According to the research report titled ‘Nannochloropsis Market Size, Share, Forecast, & Trends Analysis by Form (Frozen, Liquid, Powder, Fresh Pastes), Application (Aquafeed, Extraction Companies)-Global Forecast to 2031,’ the Nannochloropsis market is projected to reach $14.0 million by 2031, at a CAGR of 8.5% from 2024 to 2031. In terms of volume, the Nannochloropsis market is projected to reach 122 tons by 2031, at a CAGR of 9.4% during the forecast period of 2024-2031. The report provides an in-depth analysis of the Nannochloropsis market across five major geographies, current market trends, size, and recent developments, and the forecast till 2031.Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of the Nannochloropsis market is driven by the increasing demand for algal protein, the growing demand for protein-rich and lipid-rich aquafeed, and the rising demand for omega-3 fatty acids. However, the complex production process of Nannochloropsis restrains the growth of this market.Furthermore, the growing demand from the biodiesel industry is expected to offer market growth opportunities. However, the risk of Nannochloropsis contamination is a major challenge impacting the growth of the Nannochloropsis market.Key PlayersThe key players operating in the Nannochloropsis market are Proviron Industries NV (Belgium), Reed Mariculture Inc. (U.S.), Necton S.A. (Portugal), BlueBioTech Group (Germany), Allmicroalgae Natural Products S.A. (Portugal), Algatechnologies Ltd. (A Part of Solabia Group) (Israel), A4f Algae for Future (Portugal), Green Aqua Company SGPS S.A. (Portugal), AlgaSpring B.V. (Netherlands), Archimede Ricerche S.r.l (Italy), Astaxa GmbH (Germany), and Shaivaa Algaetech LLP (India).Based on form, the Nannochloropsis market is segmented into frozen, liquid, powder, and fresh pastes. In terms of value, in 2024, the frozen segment is expected to account for the largest share of 61.5% of the Nannochloropsis market. The large market share of this segment is attributed to the higher adoption of frozen Nannochloropsis in aquafeed applications, especially in aquaculture hatcheries to establish the initial step of an artificial food chain considering its high nutritional value and rich source of fatty acids (EPA, ARA). Moreover, this segment is also projected to register the highest CAGR of 8.9% during the forecast period of 2024-2031 because frozen Nannochloropsis biomass promotes easier management in biomass production of lipid-enriched rotifers.Based on application, the Nannochloropsis market is segmented into aquafeed, extraction companies, and other applications. In 2024, the aquafeed segment is expected to account for the largest share of 72.9% of the Nannochloropsis market. The segment’s large share is attributed to the extensive use of Nannochloropsis sp. in aquaculture due to its nutritional value and ability to produce valuable chemical compounds, such as pigments (zeaxanthin, astaxanthin, and canthaxanthin) and polyunsaturated fatty acids.An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major geographies (Asia-Pacific, Europe, North America, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2024, Europe is expected to account for the largest share of 35.7% of the Nannochloropsis market. Europe’s major market share is attributed to the growing aquaculture industry and need for aquafeed, increasing health awareness, rising demand for omega-3 fatty acids, and increasing demand for algae protein. Additionally, the growing demand from the biodiesel industry is expected to create lucrative opportunities for Nannochloropsis manufacturers in the region.Key Questions Answered in the Report:What is the value of revenue generated by the Nannochloropsis market?At what rate is the global demand for Nannochloropsis projected to grow for the next 5-7 years?What is the historical market size and growth rate for the Nannochloropsis market?What are the major factors impacting the growth of this market at global and regional levels?What are the major opportunities for existing players and new entrants in the market?Which form and application segments create major traction for the manufacturers in this market?What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the Nannochloropsis market?Who are the major players in the Nannochloropsis market? What are their specific product offerings in this market?What recent developments have taken place in the Nannochloropsis market? What impact have these strategic developments created on the market?Scope of the Report:Nannochloropsis Market Assessment - by FormFrozenLiquidPowderFresh PastesNannochloropsis Market Assessment - by ApplicationAquafeedExtraction CompaniesOther ApplicationsNannochloropsis Market Assessment - by GeographyNorth AmericaU.S.CanadaEuropeSpainPortugalGermanyItalyFranceU.K.DenmarkSwedenRest of EuropeAsia-PacificChinaJapanIndiaAustraliaRest of Asia-PacificLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East and AfricaEgyptSaudi ArabiaSouth AfricaUAERest of Middle East & Africa